KPV 10mg
A research-use tripeptide entry for inflammatory-response literature and safety review.
Contents
Use this guide as a structured review page. The same headings appear for every protocol so clients and the care team can scan the page consistently.
Quickstart Highlights
KPV (Lysine–Proline–Valine) is a C‑terminal tripeptide fragment of α‑melanocyte‑stimulating hormone (α‑MSH) studied for its potent anti‑inflammatory properties without melanotropic side effects[1][2]. Research demonstrates KPV reduces pro‑inflammatory cytokines in models of inflammatory bowel disease and systemic inflammation[3]. This educational protocol presents a once‑daily subcutaneous approach using a practical dilution for precise insulin‑syringe measurements.
- Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.
- Typical daily range: 200–500 mcg once daily (gradual titration recommended).
- Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.33 mcg on a U‑100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F) or below; after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 30 days; avoid freeze–thaw cycles.
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Week 1 | 200 mcg | 6 units (0.06 mL) |
| Week 2 | 300 mcg | 9 units (0.09 mL) |
| Week 3 | 400 mcg | 12 units (0.12 mL) |
| Weeks 4–8 | 500 mcg | 15 units (0.15 mL) |
- Frequency: Inject once daily subcutaneously. This schedule uses the largest practical dilution (3.0 mL) to maintain manageable injection volumes. For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability and more precise measurement[10].
Reconstitution Steps
Reference-derived details for KPV 10mg.
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Supplies Needed
Plan based on an 8–16 week daily protocol with gradual titration.
- Peptide Vials (KPV, 10 mg each):
- Peptide Vials (KPV, 10 mg each):: 8 weeks ≈ 3 vials
- Peptide Vials (KPV, 10 mg each):: 12 weeks ≈ 4 vials
- Peptide Vials (KPV, 10 mg each):: 16 weeks ≈ 6 vials
- Insulin Syringes (U‑100):
- Insulin Syringes (U‑100):: Per week: 7 syringes (1/day)
- Insulin Syringes (U‑100):: 8 weeks: 56 syringes
- Insulin Syringes (U‑100):: 12 weeks: 84 syringes
- Insulin Syringes (U‑100):: 16 weeks: 112 syringes
- Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.: 8 weeks (3 vials): 9 mL → 1 × 10 mL bottle
- Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.: 12 weeks (4 vials): 12 mL → 2 × 10 mL bottles
- Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.: 16 weeks (6 vials): 18 mL → 2 × 10 mL bottles
- Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Alcohol Swabs: One for the vial stopper + one for the injection site each day.: Per week: 14 swabs (2/day)
- Alcohol Swabs: One for the vial stopper + one for the injection site each day.: 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- Alcohol Swabs: One for the vial stopper + one for the injection site each day.: 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- Alcohol Swabs: One for the vial stopper + one for the injection site each day.: 16 weeks: 224 swabs → recommend 3 × 100‑count boxes
Protocol Overview
Concise summary of the once‑daily regimen.
- Goal: Support reduction of systemic inflammation and modulate immune responses without melanotropic effects[1][3]. Open source
- Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
- Dose Range: 200–500 mcg daily with gradual weekly titration.
- Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate unit measurements.
- Storage: Lyophilized frozen at −20 °C (−4 °F) or below; reconstituted refrigerated at 2–8 °C (35.6–46.4 °F); avoid repeated freeze–thaw.
Dosing Protocol
Suggested daily titration approach.
- Start: 200 mcg daily; increase by ~100 mcg weekly as tolerated[4][5]. Open source
- Target: 400–500 mcg daily by Weeks 4–8 for maintenance anti‑inflammatory effects.
- Frequency: Once per day (subcutaneous).
- Cycle Length: 8–12 weeks; optional extension to 16 weeks under monitoring.
- Timing: Any consistent time; rotate injection sites systematically.
Storage Instructions
Proper storage preserves peptide quality and stability.
- Lyophilized: Store at −20 °C (−4 °F) or below in dry, dark conditions; protect from moisture and light[6][7]. Open source
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within approximately 30 days[7]. Open source
- Allow vials to reach room temperature before opening to minimize condensation uptake.
- Avoid freeze–thaw cycles: Do not refreeze reconstituted peptide solutions; prepare aliquots if long‑term storage is needed[6]. Open source
Important Notes
Practical considerations for consistency and safety.
- Use new sterile insulin syringes for each administration; dispose in a sharps container immediately after use.
- Rotate injection sites systematically (abdomen, thighs, upper arms) at least 1–2 inches apart to reduce local irritation and prevent lipohypertrophy[8]. Open source
- Inject slowly; wait a few seconds before withdrawing the needle to prevent solution backflow.
- Document daily dose, injection site, and any observations to maintain consistency and track tolerability.
- If injection‑site reactions (redness, mild swelling) occur, apply a cool compress and monitor; persistent reactions warrant protocol review.
How This Works
KPV is the C‑terminal tripeptide sequence (residues 11–13) of α‑melanocyte‑stimulating hormone (α‑MSH), retaining potent anti‑inflammatory activity without the hormone’s melanotropic effects[1][2]. Preclinical studies demonstrate KPV reduces pro‑inflammatory cytokines (TNF‑α, IL‑6, IL‑1β) and modulates immune cell activity in models of inflammatory bowel disease, colitis, and systemic inflammation[3]. The peptide’s mechanism involves inhibition of nuclear factor kappa B (NF‑κB) signaling and modulation of inflammatory mediator release[2]. Subcutaneous administration provides systemic delivery with rapid absorption and sustained anti‑inflammatory effects observed in daily dosing protocols[4].
Potential Benefits & Side Effects
Observations from preclinical and early‑stage research.
- Anti‑inflammatory activity: Reduces pro‑inflammatory cytokines and modulates immune responses in models of inflammatory bowel disease and systemic inflammation[3]. Open source
- Oral and subcutaneous efficacy: Multiple routes of administration show activity, with subcutaneous injection favored for systemic delivery and consistent bioavailability[4]. Open source
- Wound healing support: Preclinical data suggest KPV may support tissue repair and wound healing processes through inflammatory modulation[5]. Open source
- Generally well tolerated: Occasional mild injection‑site reactions (redness, slight swelling) may occur; systemic side effects are rarely reported in research protocols.
- No melanotropic effects: Unlike full α‑MSH, KPV does not affect melanocyte activity or skin pigmentation[1]. Open source
Lifestyle Factors
Complementary strategies for optimizing inflammatory balance.
- Anti‑inflammatory diet: Emphasize whole foods, omega‑3 fatty acids, polyphenols, and minimize processed foods and refined sugars.
- Stress management: Chronic stress elevates inflammatory markers; incorporate stress‑reduction practices (meditation, yoga, adequate sleep).
- Physical activity: Regular moderate exercise supports healthy inflammatory balance; avoid overtraining which can increase inflammation.
- Sleep optimization: Prioritize 7–9 hours of quality sleep nightly to support immune regulation and inflammatory homeostasis.
- Gut health: Support microbiome diversity through probiotic‑rich foods and adequate fiber intake, particularly relevant for inflammatory bowel conditions.
Injection Technique
General subcutaneous guidance from clinical best‑practice resources[8][9].
- Clean the vial stopper and injection site with alcohol swabs; allow to dry completely (10–15 seconds).
- Pinch a 1–2 inch skinfold; insert the needle at 45–90° angle into subcutaneous tissue[8]. Open source
- Do not aspirate for subcutaneous injections; inject slowly and steadily over 3–5 seconds.
- Withdraw the needle smoothly and apply gentle pressure with a clean alcohol swab (do not rub the site).
- Rotate sites systematically using a pattern (e.g., alternating between right/left abdomen, right/left thigh) to avoid lipohypertrophy and maintain consistent absorption[9]. Open source
- Preferred sites: abdomen (at least 2 inches from navel), anterior/lateral thigh, or outer upper arm (if administering to self, abdomen and thigh are easiest).
Recommended Source
We recommend Prime Lab Peptides for high‑purity KPV (10 mg).
- High‑purity peptides with third‑party testing and batch‑specific certificates of analysis (COAs).
- Consistent quality control and ISO‑aligned handling procedures.
- Reliable fulfillment with proper cold‑chain packaging to maintain peptide integrity during shipping.
- Transparent batch documentation and customer support for research applications.
Important Note
This page is informational and does not authorize use. Peptify clients should complete assessment, disclose medications and health history, and follow the clinician-approved plan only.
- Do not start, stop, combine, or change a protocol based only on website content.
- Emergency symptoms require urgent medical care, not a website or routine follow-up message.
References
Reference-derived details for KPV 10mg.
- KPV (10mg Vial) Open source
- Journal of Pharmaceutical Drug Delivery Research (2022) — Pawar K. et al.: KPV as an α‑MSH fragment retains potent anti‑inflammatory activity without melanotropic side effects View Source Open source
- FASEB Journal (2003) — Brzoska T. et al.: α‑MSH and related tripeptides: modulation of colitis, inflammation, and melanocortin receptors View Source Open source
- Gastroenterology (2008) — Dalmasso G. et al.: PepT1‑mediated tripeptide KPV uptake reduces intestinal inflammation in DSS colitis models View Source Open source
- Innerbody Research (2025) — KPV peptide benefits, safety, and administration routes; subcutaneous injection for systemic therapy View Source Open source
- Peptides.org Dosage Guide (2023) — KPV dosage calculator and protocol: 200–400 mcg subcutaneously once daily for inflammation and wound healing View Source Open source
- Bachem (Peptide Handling Guidelines) — Long‑term peptide stability best achieved in lyophilized form at <−15 °C; avoid extended storage in solution View Source Open source
- PeptideSciences (Storage Guidelines) — Lyophilized peptides stable for short‑term at 4 °C, long‑term at −20 °C; reconstituted solutions refrigerated up to ~30 days View Source Open source
- Johns Hopkins Arthritis Center — Subcutaneous injection technique: site preparation, needle angle (45–90°), and injection site rotation View Source Open source
- NCBI Bookshelf (Clinical Procedures) — Best practices for injection: aseptic technique, site preparation, and administration procedures View Source Open source
- dosagepeptide.com (KPV 10mg Protocol) — Reconstitution in 3 mL yields 3.33 mg/mL; unit/mL conversions; precision syringe recommendations for low volumes View Source Open source
- CDC Vaccine Administration — Subcutaneous injection route guidance: needle angle, site selection, and no aspiration for subcut injections View Source Open source
- PMC (Subcutaneous Drug Injection Review) — Pharmacologic and physiologic considerations of the subcutaneous route for drug administration View Source Open source
- Prime Lab Peptides — KPV (10 mg) product page: quality documentation, batch COAs, and research‑grade peptide supplier View Source